Creative Planning
VTVT icon

Creative Planning’s vTv Therapeutics VTVT Stock Holding History

Creative Planning’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-475
Closed -$114K – 2131
2017
Q4 		$114K Buy
+475
New +$106K ﹤0.01% 1710
2017
Q1 		– Sell
-25
Closed -$5K – 4924
2016
Q4 		$5K Buy
+25
New +$5.75K ﹤0.01% 3979

Other funds holding VTVT

GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Creative Planning's VTVT Position: Q1 2018 in Review

Creative Planning sold out of vTv Therapeutics (VTVT) in Q1 2018, closing a stake of 475 shares — an estimated $114K sold.

Creative Planning first reported a position in VTVT in Q4 2016 and held it in 2 quarters. The position peaked at $114K in Q4 2017. 41 funds tracked by Wall St. Rank hold VTVT as of Q1 2018.

  • Creative Planning reported no remaining vTv Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Creative Planning sold 475 vTv Therapeutics shares in Q1 2018, an estimated $114K.
  • Creative Planning first reported a position in vTv Therapeutics in Q4 2016 and held it in 2 quarters.
  • Creative Planning's vTv Therapeutics position peaked at $114K in Q4 2017.
  • 41 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2018.

Based on Creative Planning's 13F filing for Q1 2018, filed 18 Apr 2018.